

In the claims

21. (Original) A composition comprising a pharmaceutically effective amount of a TGF- β antagonist and an immunosuppressive agent.
22. (Original) The composition according to claim 21 wherein TGF- β antagonist is an anti-TGF- β antibody or an antigen-binding fragment thereof.
23. (Original) The composition according to claim 21 wherein the TGF- β antagonist inhibits the activity of TGF- β 1.
24. (Original) The composition according to claim 21 wherein the TGF- β antagonist inhibits the activity of TGF- β 2.
25. (Original) The composition according to claim 21 wherein the TGF- β antagonist inhibits the activity of TGF- β 3.
26. (Original, withdrawn by the Examiner) The composition according to claim 21 wherein the TGF- β antagonist binds a TGF- β receptor
27. (Original) The composition according to claim 21 wherein the TGF- β antagonist inhibits the activity of more than one isoform of TGF- β .
28. (Original, withdrawn by the Examiner) The composition according to claim 21 wherein the TGF- β antagonist is a soluble TGF- β receptor.

BEST-AVAILABLE COPY

29. (Original, withdrawn by the Examiner) The composition according to claim 21 wherein the TGF- β antagonist is a protein selected from the group consisting of decorin, fetuin, and fibromodulin.
30. (Original) The composition according to claim 21 wherein the immunosuppressive agent is cyclosporine.
31. (Original) The composition according to claim 21 wherein the immunosuppressive agent is FK506.

BEST AVAILABLE COPY